[144] GENPACT LIMITED SEC Filing

Rhea-AI Filing Summary

Genpact Limited (G) submitted a Form 144 notifying a proposed sale of 20,078 common shares via Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $903,510 and an approximate sale date of 08/28/2025. The filing shows the shares were acquired on 01/10/2025 from the issuer as 12,236 restricted stock and 7,842 performance shares, with payment dates listed as 01/10/2025 and no cash financing arrangements disclosed. The total outstanding common shares noted are 174,270,076, so the proposed sale represents a de minimis portion of the outstanding float. The filer certifies no undisclosed material adverse information and no sales in the past three months are reported.

Positive

• Disclosure complies with Rule 144 and provides broker, share count, and acquisition details
• Shares originate from issuer grants (restricted stock and performance shares), not third-party purchases
• Proposed sale is immaterial relative to 174,270,076 shares outstanding (~0.01%)

Negative

• Insider sale announced for 20,078 shares valued at $903,510, which some investors may view unfavorably despite small size
• No detail about whether a trading plan (e.g., Rule 10b5-1) governs the sale is provided in the visible text

Insights

Securities Analyst

TL;DR: Routine insider sale notice of newly issued restricted and performance stock; immaterial to capitalization.

The Form 144 documents a proposed brokered sale of 20,078 shares valued at $903,510, derived from restricted stock and performance share grants issued on 01/10/2025. Relative to the 174.27 million shares outstanding, this represents roughly 0.01% of outstanding shares, indicating the transaction is unlikely to affect market supply or valuation materially. The filing includes the standard issuer-related representation and indicates no prior sales in the last three months. As presented, this is a compliance disclosure rather than a material corporate event.

Corporate Governance Specialist

TL;DR: Compliance-driven disclosure of executive or insider sale tied to equity awards, with standard certifications.

The notice shows the securities were issued by the company and acquired as restricted stock and performance shares on the same date, suggesting post-grant sale of equity compensation. The filer affirms absence of undisclosed material adverse information, and no aggregation of prior three-month sales is reported. From a governance perspective, this aligns with routine reporting obligations under Rule 144 and does not, on its face, indicate atypical insider behavior or governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20078	903510.00	174270076	08/28/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/10/2025	Restricted Stock	Issuer			12236	01/10/2025	Not Applicable
Common	01/10/2025	Performance Shares	Issuer			7842	01/10/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Genpact's Form 144 filing for G disclose?

The filing notifies a proposed sale of 20,078 common shares through Morgan Stanley Smith Barney valued at $903,510, with an approximate sale date of 08/28/2025.

What type of shares are being sold in the G Form 144?

The shares consist of 12,236 restricted stock and 7,842 performance shares acquired from the issuer on 01/10/2025.

How large is the proposed sale relative to Genpact's outstanding shares?

The sale represents about 20,078 of 174,270,076 outstanding shares, roughly 0.01% of the outstanding common shares.

Did the filer sell any Genpact shares in the past three months?

No sales in the past three months are reported in the filing.

Which broker will handle the proposed sale disclosed in the Form 144?

Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, New York, NY is listed as the broker.